Browsing by author "McLaughlin, Martin"
Now showing items 1-15 of 15
-
An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation.
Patel, R; Barker, HE; Kyula, J; McLaughlin, M; Dillon, MT; et al. (2017-03)Purpose Chk1 inhibition increases cell sensitivity to both chemotherapy and radiotherapy in several tumour types and is, therefore, a promising anti-cancer approach. Although several Chk1 inhibitors have been developed, ... -
An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation.
Patel, R; Barker, HE; Kyula, J; McLaughlin, M; Dillon, MT; et al. (ELSEVIER IRELAND LTD, 2017-03-01)PURPOSE: Chk1 inhibition increases cell sensitivity to both chemotherapy and radiotherapy in several tumour types and is, therefore, a promising anti-cancer approach. Although several Chk1 inhibitors have been developed, ... -
ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment.
Dillon, MT; Bergerhoff, KF; Pedersen, M; Whittock, H; Crespo-Rodriguez, E; et al. (AMER ASSOC CANCER RESEARCH, 2019-06-01)PURPOSE: ATR inhibitors (ATRi) are in early phase clinical trials and have been shown to sensitize to chemotherapy and radiotherapy preclinically. Limited data have been published about the effect of these drugs on the ... -
CD4 T cell dynamics shape the immune response to combination oncolytic herpes virus and BRAF inhibitor therapy for melanoma.
Bozhanova, G; Hassan, J; Appleton, L; Jennings, V; Foo, S; et al. (BMJ PUBLISHING GROUP, 2022-03-01)BACKGROUND: Combination herpes simplex virus (HSV) oncolytic virotherapy and BRAF inhibitors (BRAFi) represent promising immunogenic treatments for BRAF mutant melanoma, but an improved understanding of the immunobiology ... -
CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy.
Barker, HE; Patel, R; McLaughlin, M; Schick, U; Zaidi, S; et al. (AMER ASSOC CANCER RESEARCH, 2016-09-01)Head and neck squamous cell carcinoma (HNSCC) is a leading cause of cancer-related deaths, with increasingly more cases arising due to high-risk human papillomavirus (HPV) infection. Cisplatin-based chemoradiotherapy is a ... -
Combination therapy with oncolytic viruses and immune checkpoint inhibitors.
Chiu, M; Armstrong, EJL; Jennings, V; Foo, S; Crespo-Rodriguez, E; et al. (TAYLOR & FRANCIS LTD, 2020-06-02)Introduction: Immune checkpoint inhibitors (ICI) have dramatically improved the outcome for cancer patients across multiple tumor types. However the response rates to ICI monotherapy remain relatively low, in part due to ... -
Combined ATR and DNA-PK Inhibition Radiosensitizes Tumor Cells Independently of Their p53 Status.
Hafsi, H; Dillon, MT; Barker, HE; Kyula, JN; Schick, U; et al. (FRONTIERS MEDIA SA, 2018-07-13)Head and neck squamous cell carcinoma (HNSCC) is a significant cause of cancer deaths. Cisplatin-based chemoradiotherapy is a standard of care for locally advanced disease. ATR and DNA-PK inhibition (DNA-PKi) are actively ... -
Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues.
Khan, AA; Paget, JT; McLaughlin, M; Kyula, JN; Wilkinson, MJ; et al. (AMER ASSOC ADVANCEMENT SCIENCE, 2018-01-24)Improvements in cancer survival mean that long-term toxicities, which contribute to the morbidity of cancer survivorship, are being increasingly recognized. Late adverse effects (LAEs) in normal tissues after radiotherapy ... -
Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade.
Patin, EC; Dillon, MT; Nenclares, P; Grove, L; Soliman, H; et al. (BMJ PUBLISHING GROUP, 2022-03-01)BACKGROUND: Despite therapeutic gains from immune checkpoint inhibitors (ICI) in many tumor types, new strategies are needed to extend treatment benefits, especially in patients failing to mount effective antitumor T-cell ... -
HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation.
McLaughlin, M; Barker, HE; Khan, AA; Pedersen, M; Dillon, M; et al. (BIOMED CENTRAL LTD, 2017-01-31)BACKGROUND: Concurrent cisplatin radiotherapy (CCRT) is a current standard-of-care for locally advanced head and neck squamous cell carcinoma (HNSCC). However, CCRT is frequently ineffective in patients with advanced ... -
Inflammatory microenvironment remodelling by tumour cells after radiotherapy.
McLaughlin, M; Patin, EC; Pedersen, M; Wilkins, A; Dillon, MT; et al. (NATURE PORTFOLIO, 2020-04-01)The development of immune checkpoint inhibitors (ICIs) is revolutionizing the way we think about cancer treatment. Even so, for most types of cancer, only a minority of patients currently benefit from ICI therapies. Intrinsic ... -
Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer.
Mansfield, DC; Kyula, JN; Rosenfelder, N; Chao-Chu, J; Kramer-Marek, G; et al. (NATURE PUBLISHING GROUP, 2016-04-01)Oncolytic strains of vaccinia virus are currently in clinical development with clear evidence of safety and promising signs of efficacy. Addition of therapeutic genes to the viral genome may increase the therapeutic efficacy ... -
PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma.
Smith, HG; Mansfield, D; Roulstone, V; Kyula-Currie, JN; McLaughlin, M; et al. (AMER ASSOC CANCER RESEARCH, 2019-06-01)PURPOSE: The prevention and treatment of metastatic sarcoma are areas of significant unmet need. Immune checkpoint inhibitor monotherapy has shown little activity in sarcoma and there is great interest in identifying novel ... -
Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.
Dillon, MT; Barker, HE; Pedersen, M; Hafsi, H; Bhide, SA; et al. (AMER ASSOC CANCER RESEARCH, 2017-01-01)AZD6738 is an orally active ATR inhibitor (ATRi) currently in phase I clinical trials. We found in vitro growth inhibitory activity of this ATRi in a panel of human cancer cell lines. We demonstrated radiosensitization by ... -
The PERK Inhibitor GSK2606414 Enhances Reovirus Infection in Head and Neck Squamous Cell Carcinoma via an ATF4-Dependent Mechanism.
McLaughlin, M; Pedersen, M; Roulstone, V; Bergerhoff, KF; Smith, HG; et al. (CELL PRESS, 2020-03-27)Reovirus type 3 Dearing (reovirus) is a tumor-selective oncolytic virus currently under evaluation in clinical trials. Here, we report that the therapeutic efficacy of reovirus in head and neck squamous cell cancer can be ...